BGLC 最新10-Q变化
将 BGLC 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-15
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +67 | −42 | ~14 | 25 |
| 市场风险(第3项) | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 控制与程序 | 文字有新增/删除 | +2 | −4 | ~2 | 9 |
| 法律诉讼 | 文字有新增/删除 | +2 | −2 | 0 | 0 |
| 风险因素 | 部分风险因素更新 | +3 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
During the quarter ended June 30, 2026, BioNexus Gene Lab Corp. ("BGLC", the "Company", "we", "us" or "our") continued to refine its strategic focus across healthcare diagnostics through MRNA Scientific Sdn. Bhd., specialty chemicals through Chemrex Corporation Sdn. Bhd., and its investment and stra…
These activities remain subject to the technical, regulatory, financing, contractual and operational requirements, uncertainties and risks described in this report.
The Company continues to evaluate capital-raising alternatives, which may include at-the-market offerings, private placements or strategic financing arrangements, subject to market conditions, corporate authorization, Nasdaq and SEC requirements and the Company's capital needs.
On November 28, 2025, the Company completed the Share Subscription and Shareholders’ Agreement with Fidelion and the other parties thereto. The Company also entered into an Intellectual Property License Agreement with Fidelion under which the Company obtained exclusive, perpetual commercialization r…
In January 2026, the Company announced the formal commencement of the deployment phase for VitaGuard. During the quarter ended June 30, 2026, the Company’s activities remained focused on commercialization planning and implementation, including coordination with Fidelion, Tongshu Biotechnology (Hong …
相对上期删除的文字 · 来源:10-Q · 2026-05-15
During the current quarter ended March 31, 2026, BioNexus Gene Lab Corp. ("BGLC", the “Company”, “we”, “us” or “our”) continued to develop and refine its strategic focus across its three operational segments: healthcare diagnostics (MRNA Scientific Sdn. Bhd.), specialty chemicals (Chemrex Corporatio…
We successfully completed the integration of Nasdaq-listed operations following our 2023 uplisting, while maintaining a stable liquidity position and initiating expansion into the digital healthcare and decentralized asset infrastructure sectors.
In light of the recent governance enhancements and upcoming growth initiatives, including expansion into digital health and decentralized financial infrastructure, the Company is actively exploring additional capital-raising mechanisms. These may include at-the-market offerings, private placements, …
Thereafter, on November 28, 2025, the Company completed a Share Subscription and Shareholders’ Agreement with Fidelion, among others. The parties also entered into an Intellectual Property License Agreement, pursuant to which the Company obtained exclusive commercial rights to the VitaGuard™ Minimal…
In January 2026, the Company announced the formal commencement of the deployment phase for the VitaGuard™ MRD platform in connection with its licensing arrangement. In connection with the advancement of the MRD platform, during the current quarter, the Company has focused on its plans for commercial…
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-14
The Company is not required to provide an attestation report from its registered public accounting firm under Section 404(b) of the Sarbanes-Oxley Act of 2002 because it is a non-accelerated filer.
Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). As of June 30, 2026, management concluded that the Company did not maintain effective internal control over financial reporting because…
相对上期删除的文字 · 来源:10-Q · 2026-05-15
Management’s Report on Internal Control over Financial Reporting
The Company is not required to provide an attestation report from its registered public accounting firm pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002 as it qualifies as a smaller reporting company.
Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of internal control over financial reporting as of December 31, 2024, using the…
Based on this assessment, management concluded that the Company did not maintain effective control over financial reporting as of the end of the period covered by this report, for the reasons reported below.
法律诉讼
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Except as described below, the Company is not a party to any material pending legal proceeding, and no such proceeding is known by the Company to be threatened or contemplated.
As previously disclosed, on May 13, 2026, the Company issued Letters of Demand to the five former officers and directors of Chemrex demanding that the former officers and directors repay to Chemrex the collective sum of approximately $2,944,000 within 14 days. Based on its ongoing investigation, the…
相对上期删除的文字 · 来源:10-Q · 2026-05-15
Except as stated herein, there are presently no legal proceedings filed to date to which the Company or any of its property is subject, or any material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than five percent of any class o…
As disclosed elsewhere herein, on May 13, 2026, the Company issued Letters of Demand to the five former officers and directors of Chemrex demanding that the former officers and directors repay to Chemrex the collective sum of approximately $2,944,000 within 14 days. The former officers and directors…
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Our commercialization of VitaGuard depends on completion of customary post-closing verification, perfection and implementation work, as well as regulatory and operational readiness, and we may not generate revenue from the platform.
The principal transaction agreements relating to VitaGuard, including the IPTA between Tongshu and Fidelion and the Company’s License Agreement with Fidelion, have been executed. The Company believes that it and Fidelion are entitled to rely upon the executed agreements in accordance with their term…
Although the Company believes the executed agreements provide a sufficient contractual basis to proceed with commercialization activities, uncertainties remain regarding the timing and completion of this verification, perfection and implementation work. Errors or omissions in transaction schedules, …
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议